Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PDE8B | O95263 | 1/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14322076 | 0.94 | LMNA (0.50) | LMNAPOLBUSP2SMN1; SMN2HPGD | |
| Hydrochloric Acid SCHEMBL27859545 | 0.89 | LMNA (0.41) | LMNAPOLBUSP2SMN1; SMN2HPGD | |
| SCHEMBL1705701 | 0.89 | HPGD (0.51) | LMNAPOLBUSP2SMN1; SMN2HPGD | |
| SCHEMBL2656786 | 0.85 | LMNA (0.47) | LMNAPOLBUSP2SMN1; SMN2HPGD | |
| SCHEMBL1916142 | 0.80 | ALDH1A1 (0.49) | LMNAPOLBUSP2SMN1; SMN2HPGD | |
| SCHEMBL2398531 | 0.80 | ALDH1A1 (0.49) | LMNAPOLBUSP2SMN1; SMN2HPGD | |
| SCHEMBL2398393 | 0.80 | ALDH1A1 (0.49) | LMNAPOLBUSP2SMN1; SMN2HPGD | |
| SCHEMBL23501583 | 0.80 | LMNA (0.51) | LMNAPOLBUSP2SMN1; SMN2HPGD | |
| SCHEMBL15822139 | 0.80 | EPHX1 (0.48) | LMNAPOLBUSP2SMN1; SMN2HPGD | |
| SCHEMBL2481405 | 0.79 | ALDH1A1 (0.56) | LMNAPOLBUSP2SMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296698-B2 | Amino heteroaryl compounds as beta-secretase modulators and methods of use | AMGEN INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20120329830-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | AMGEN INC. (US) | 2012-12-27 | — | — | US | disclosed |
| EP-2504315-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | Amgen Inc. (US) | 2012-10-03 | — | — | EP | disclosed |
| WO-2011063233-A1 | AMINO HETEROARYL COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE | AMGEN INC. (US) | 2011-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120329830-A1 | Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use | BACE1, BACE2, APP | LMNA 1486/4885POLB 1921/4885USP2 2045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.